UNLABELLED: Monitoring hepatic function in children with short bowel syndrome (SBS) and parenteral nutrition-associated liver disease (PNALD) is currently limited to conventional blood testing or liver biopsy. Metabolism of the stable isotope L[1-(13)C]methionine occurs exclusively in liver mitochondria and can be noninvasively quantified in expired breath samples. We hypothesized that the (13)C-methionine breath test ((13)C-MBT) could be a safe, noninvasive, and valid measure of hepatic mitochondrial function in children with SBS and PNALD. METHODS: Baseline breath samples were collected in 8 children with SBS before intravenous administration of 2 mg/kg of L[1-(13)C]methionine. Six paired breath samples were obtained at 20-minute intervals. The (13)CO(2) enrichment was analyzed using isotope ratio mass spectrometry. RESULTS: All 8 patients (5 males; mean age, 8.9 months) tolerated the (13)C-MBT without adverse events. Two patients underwent serial testing. One patient, tested before and after resolution of cholestasis, demonstrated increased cumulative percentage dose (4.7% to 6.6%) and area under the curve (AUC) (270-303). A second patient with progressive PNALD demonstrated decreased cumulative percentage dose (from 7.8% to 5.9%) and AUC (from 335 to 288). CONCLUSION: The (13)C-MBT is a feasible, safe, and potentially clinically relevant measure of hepatic mitochondrial function in children with SBS and PNALD.
UNLABELLED: Monitoring hepatic function in children with short bowel syndrome (SBS) and parenteral nutrition-associated liver disease (PNALD) is currently limited to conventional blood testing or liver biopsy. Metabolism of the stable isotope L[1-(13)C]methionine occurs exclusively in liver mitochondria and can be noninvasively quantified in expired breath samples. We hypothesized that the (13)C-methionine breath test ((13)C-MBT) could be a safe, noninvasive, and valid measure of hepatic mitochondrial function in children with SBS and PNALD. METHODS: Baseline breath samples were collected in 8 children with SBS before intravenous administration of 2 mg/kg of L[1-(13)C]methionine. Six paired breath samples were obtained at 20-minute intervals. The (13)CO(2) enrichment was analyzed using isotope ratio mass spectrometry. RESULTS: All 8 patients (5 males; mean age, 8.9 months) tolerated the (13)C-MBT without adverse events. Two patients underwent serial testing. One patient, tested before and after resolution of cholestasis, demonstrated increased cumulative percentage dose (4.7% to 6.6%) and area under the curve (AUC) (270-303). A second patient with progressive PNALD demonstrated decreased cumulative percentage dose (from 7.8% to 5.9%) and AUC (from 335 to 288). CONCLUSION: The (13)C-MBT is a feasible, safe, and potentially clinically relevant measure of hepatic mitochondrial function in children with SBS and PNALD.
Authors: D J Andorsky; D P Lund; C W Lillehei; T Jaksic; J Dicanzio; D S Richardson; S B Collier; C Lo; C Duggan Journal: J Pediatr Date: 2001-07 Impact factor: 4.406
Authors: L Spahr; F Negro; L Rubbia-Brandt; O Marinescu; K Goodman; M Jordan; J L Frossard; A Hadengue Journal: Dig Dis Sci Date: 2001-12 Impact factor: 3.199
Authors: Reinout C A Schellekens; Frans Stellaard; Herman J Woerdenbag; Henderik W Frijlink; Jos G W Kosterink Journal: Br J Clin Pharmacol Date: 2011-12 Impact factor: 4.335
Authors: Debora Duro; Paul D Mitchell; Nilesh M Mehta; Lori J Bechard; Yong-Ming Yu; Tom Jaksic; Christopher Duggan Journal: J Pediatr Gastroenterol Nutr Date: 2014-05 Impact factor: 2.839
Authors: Shimae C Fitzgibbons; Brian A Jones; Melissa A Hull; David Zurakowski; Debora Duro; Christopher Duggan; Dana Boctor; David L Sigalet; Tom Jaksic Journal: J Pediatr Surg Date: 2010-01 Impact factor: 2.545